{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:27:53Z","timestamp":1771342073872,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12185-025-04089-8","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:00:51Z","timestamp":1761915651000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective analysis of clinicopathological and genetic features of synchronous CNS and systemic DLBCL at diagnosis"],"prefix":"10.1007","volume":"123","author":[{"given":"Kayo Egoshi","family":"Ohashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2423-9978","authenticated-orcid":false,"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"4089_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/bjh.16064","volume":"187","author":"JC Wight","year":"2019","unstructured":"Wight JC, Yue M, Keane C, Johnston A, Linton K, Chin C, et al. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. Br J Haematol. 2019;187:174\u201384.","journal-title":"Br J Haematol"},{"key":"4089_CR2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ajh.25558","volume":"94","author":"C Perry","year":"2019","unstructured":"Perry C, Ben Barouch S, Goldschmidt N, Sarid N, Herishanu Y, Shvidel L, et al. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: a retrospective multicenter study. Am J Hematol. 2019;94:992\u20131001.","journal-title":"Am J Hematol"},{"key":"4089_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3324\/haematol.2015.126110","volume":"100","author":"G Damaj","year":"2015","unstructured":"Damaj G, Ivanoff S, Coso D, Ysaebert L, Choquet S, Houillier C, et al. Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. Haematologica. 2015;100:1199\u2013206.","journal-title":"Haematologica"},{"key":"4089_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1285026","volume":"58","author":"M Nijland","year":"2017","unstructured":"Nijland M, Jansen A, Doorduijn JK, Enting RH, Bromberg JEC, Kluin-Nelemans HC. Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma. Leuk Lymphoma. 2017;58:1\u20136.","journal-title":"Leuk Lymphoma"},{"key":"4089_CR5","doi-asserted-by":"publisher","first-page":"204062072211129","DOI":"10.1177\/20406207221112900","volume":"13","author":"M Fleming","year":"2022","unstructured":"Fleming M, Huang Y, Dotson E, Bond DA, Reneau J, Epperla N, et al. Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study. Ther Adv Hematol. 2022;13:20406207221112900.","journal-title":"Ther Adv Hematol"},{"key":"4089_CR6","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","volume":"8","author":"AJM Ferreri","year":"2021","unstructured":"Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, et al. Matrix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021;8:e110\u201321.","journal-title":"Lancet Haematol"},{"key":"4089_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.16451","volume":"189","author":"E Schorb","year":"2020","unstructured":"Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system\u2014an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189:879\u201387.","journal-title":"Br J Haematol"},{"key":"4089_CR8","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937\u201347.","journal-title":"N Engl J Med"},{"key":"4089_CR9","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1093\/oncolo\/oyac190","volume":"28","author":"EA Severson","year":"2023","unstructured":"Severson EA, Haberberger J, Hemmerich A, Huang RSP, Edgerly C, Schiavone K, et al. Genomic profiling reveals differences in primary central nervous system lymphoma and large B-cell lymphoma, with subtyping suggesting sensitivity to BTK inhibition. Oncologist. 2023;28:e26\u201335.","journal-title":"Oncologist"},{"key":"4089_CR10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"4089_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"4089_CR12","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"4089_CR13","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034\u201343.","journal-title":"J Clin Oncol"},{"key":"4089_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/jjco\/hyac034","volume":"52","author":"J Eba","year":"2022","unstructured":"Eba J, Nakamura K. Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. Jpn J Clin Oncol. 2022;52:539\u201344.","journal-title":"Jpn J Clin Oncol"},{"key":"4089_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"4089_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"4089_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse Large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551-68.e14.","journal-title":"Cancer Cell"},{"key":"4089_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00401-013-1202-x","volume":"127","author":"M Deckert","year":"2014","unstructured":"Deckert M, Montesinos-Rongen M, Brunn A, Siebert R. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol. 2014;127:175\u201388.","journal-title":"Acta Neuropathol"},{"key":"4089_CR19","doi-asserted-by":"publisher","first-page":"204062072110728","DOI":"10.1177\/20406207211072839","volume":"13","author":"R Chen","year":"2022","unstructured":"Chen R, Zhou D, Wang L, Zhu L, Ye X. MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Ther Adv Hematol. 2022;13:20406207211072840.","journal-title":"Ther Adv Hematol"},{"key":"4089_CR20","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","volume":"40","author":"C Houillier","year":"2022","unstructured":"Houillier C, Dureau S, Taillandier L, Houot R, Chinot O, Molu\u00e7on-Chabrot C, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. J Clin Oncol. 2022;40:3692\u20138.","journal-title":"J Clin Oncol"},{"key":"4089_CR21","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJM Ferreri","year":"2017","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4:e510\u201323.","journal-title":"Lancet Haematol"},{"key":"4089_CR22","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3324\/haematol.2011.060434","volume":"97","author":"C Soussain","year":"2012","unstructured":"Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquieres H, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica. 2012;97:1751\u20136.","journal-title":"Haematologica"},{"key":"4089_CR23","doi-asserted-by":"publisher","first-page":"1071281","DOI":"10.3389\/fonc.2022.1071281","volume":"12","author":"SY Jeong","year":"2022","unstructured":"Jeong SY, Yoon SE, Cho D, Kang ES, Cho J, Kim WS, et al. Real-world experiences of CNS-directed chemotherapy followed by autologous stem cell transplantation for secondary CNS involvement in relapsed or refractory diffuse large B-cell lymphoma. Front Oncol. 2022;12:1071281.","journal-title":"Front Oncol"},{"key":"4089_CR24","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3324\/haematol.2022.281640","volume":"108","author":"J Khwaja","year":"2023","unstructured":"Khwaja J, Kirkwood AA, Isbell LK, Steffanoni S, Goradia H, Pospiech L, et al. International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica. 2023;108:882\u20138.","journal-title":"Haematologica"},{"key":"4089_CR25","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3324\/haematol.2012.077917","volume":"98","author":"A Korfel","year":"2013","unstructured":"Korfel A, Elter T, Thiel E, Hanel M, Mohle R, Schroers R, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98:364\u201370.","journal-title":"Haematologica"},{"key":"4089_CR26","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","volume":"33","author":"AJ Ferreri","year":"2015","unstructured":"Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015;33:3903\u201310.","journal-title":"J Clin Oncol"},{"key":"4089_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","volume":"93","author":"TC El-Galaly","year":"2018","unstructured":"El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57\u201368.","journal-title":"Eur J Cancer"},{"key":"4089_CR28","doi-asserted-by":"publisher","first-page":"113436","DOI":"10.1016\/j.ejca.2023.113436","volume":"196","author":"S Habringer","year":"2024","unstructured":"Habringer S, Demel UM, Fietz AK, Lammer F, Schroers R, Hofer S, et al. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma. Eur J Cancer. 2024;196:113436.","journal-title":"Eur J Cancer"},{"key":"4089_CR29","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.annonc.2020.05.016","volume":"31","author":"AK McMillan","year":"2020","unstructured":"McMillan AK, Phillips EH, Kirkwood AA, Barrans S, Burton C, Rule S, et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3\u20135) treated with front-line R-CODOX-M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Ann Oncol. 2020;31:1251\u20139.","journal-title":"Ann Oncol"},{"key":"4089_CR30","doi-asserted-by":"publisher","first-page":"e926","DOI":"10.1097\/HS9.0000000000000926","volume":"7","author":"H Treiber","year":"2023","unstructured":"Treiber H, Nilius-Eliliwi V, Seifert N, Vangala D, Wang M, Seidel S, et al. Treatment strategies and prognostic factors in secondary central nervous system lymphoma: a multicenter study of 124 patients. Hemasphere. 2023;7:e926.","journal-title":"Hemasphere"},{"key":"4089_CR31","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922\u20136.","journal-title":"Nat Med"},{"key":"4089_CR32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","volume":"81","author":"L Goldwirt","year":"2018","unstructured":"Goldwirt L, Beccaria K, Ple A, Sauvageon H, Mourah S. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol. 2018;81:783\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4089_CR33","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.21037\/tcr-21-50","volume":"10","author":"H Yu","year":"2021","unstructured":"Yu H, Kong H, Li C, Dong X, Wu Y, Zhuang Y, et al. Bruton\u2019s tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution. Transl Cancer Res. 2021;10:1975\u201383.","journal-title":"Transl Cancer Res"},{"key":"4089_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, et al. Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23:122\u201333.","journal-title":"Neuro Oncol"},{"key":"4089_CR35","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018\u201329.","journal-title":"Cancer Discov"},{"key":"4089_CR36","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-24-0605","volume":"30","author":"C Grommes","year":"2024","unstructured":"Grommes C, Nandakumar S, Schaff LR, Gavrilovic I, Kaley TJ, Nolan CP, et al. A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma. Clin Cancer Res. 2024;30:4005\u201315.","journal-title":"Clin Cancer Res"},{"issue":"1643\u201353","key":"4089_CR37","first-page":"e3","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 2021;39(1643\u201353):e3.","journal-title":"Cancer Cell"},{"issue":"1705\u201316","key":"4089_CR38","first-page":"e5","volume":"41","author":"MC Zhang","year":"2023","unstructured":"Zhang MC, Tian S, Fu D, Wang L, Cheng S, Yi HM, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial. Cancer Cell. 2023;41(1705\u201316):e5.","journal-title":"Cancer Cell"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04089-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04089-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04089-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:50:46Z","timestamp":1771339846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04089-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4089"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04089-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.F. has received honoraria from Janssen, Ono, BeiGene, Nihon Shinyaku, Otsuka, Chugai, and AstraZeneca; has received grants or funding from Chugai and LOXO Oncology. D.H. has received honoraria from Chugai and Abbvie. M.W. has received honoraria from Chugai; has received grants or funding from Ono, Chugai, and Genmab. K.I. has received honoraria from MSD, AstraZeneca, Abbvie, Bristol Myers Squibb, Novartis, Yakult, Kyowa Kirin, Chugai, Beigene, Genmab, Otsuka, Ono, Mitsubishi Tanabe, Eisai, Symbio, Takeda, Zenyaku, Carna Biosciences, and Nihon Shinyaku; has received grants or funding from Ono, MSD, AstraZeneca, Abbvie, Incyte, Bristol Myers Squibb, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Daiichi Sankyo, Chugai, Beigene, Genmab, LOXO Oncology, Otsuka, Regeneron, and Gilead. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}